X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of Relapsed/Refractory mNPM1 Acute Myeloid Leukemia.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of adult and pediatric patients with relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemia.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
SNDX-5613 (revumenib) is a highly selective, oral menin inhibitor which is under phase 1 clinical development for the treatment of patients with Acute Leukemias.
Lead Product(s): Revumenib,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Revumenib is a potent, selective, small molecule inhibitor of the menin-KMT2A binding interaction that is being developed for the treatment of KMT2A-rearranged, also known as mixed lineage leukemia rearranged or MLLr, acute leukemias including ALL and AML, and NPM1-mutant AML.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
SNDX-5613 (revumenib) is an investigational, novel, orally available Menin-MLL1 inhibitor, which is investigated for the treatment of R/R KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL).
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
SNDX-5613 (revumenib) is an investigational, novel, orally available Menin-MLL1 inhibitor, which is investigated for the treatment of relapsed/refractory KMT2Ar acute leukemia.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
SNDX-5613 (revumenib) is an investigational, novel, orally available Menin-MLL1 inhibitor. The interaction of Menin and MLL1 has been demonstrated to play an essential role in the leukemic transformation for acute leukemia patients with MLLr or NPM1 mutation.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 14, 2022
Details:
SNDX-5613 (revumenib) is an investigational, novel, orally available Menin-MLL1 inhibitor.2 The interaction of Menin and MLL1 has been demonstrated to play an essential role in the leukemic transformation for acute leukemia patients with MLLr or NPM1 mutation.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
SNDX-5613 is currently being evaluated in the Company's AUGMENT-101 Phase 1/2 open-label clinical trial for the treatment of relapsed/refractory (R/R) acute leukemias.
Lead Product(s): Revumenib
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
Details:
Syndax Pharmaceuticals will host a conference call and live webcast to provide updated data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias.
Lead Product(s): Revumenib
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021
Details:
SNDX-5613 is a MLL1 inhibitor. Preliminary Phase I data revealed that inhibition of the menin-MLL1 interaction can induce response in patients with MLL-r acute leukemias.
Lead Product(s): Revumenib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
The New Drugs on the Horizon session will feature discussions of innovative small molecules and biologics that have recently entered Phase I clinical trials.
Lead Product(s): Revumenib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
Details:
Results support ongoing Phase 1/2 AUGMENT-101 trial of Syndax Pharma's SNDX-5613, for the treatment of adults with relapsed/refractory acute leukemias, including NPM1 mutant AML.
Lead Product(s): Revumenib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
